以多黏菌素为基础治疗耐碳青霉烯类革兰阴性杆菌的研究进展  

Research progress on the polymyxin based treatment of carbapenem-resistant gram-negative bacilli

作　　者：郑笑(综述) 秦海东(审校)[1] ZHENG Xiao;QIN Haidong(Department of Emergency,Nanjing Hospital Affiliated to Nanjing Medical University,Nanjing 210006,Jiangsu,China)

机构地区：[1]南京医科大学附属南京医院(南京市第一医院)急诊科,南京210006

出　　处：《医学研究与战创伤救治》2023年第8期893-896,共4页Journal of Medical Research & Combat Trauma Care

基　　金：南京市医学科技发展计划项目(YKK22115)。

摘　　要：耐碳青霉烯类革兰阴性杆菌(CR-GNB)感染已成为全球性重大公共卫生难题之一。多黏菌素主要用于CR-GNB感染的治疗,但由于多黏菌素耐药菌株及其相关不良反应的不断出现,其单药治疗的临床疗效受到了质疑。因此,以多黏菌素为基础的联合用药成为近年研究热点。文章综述了以多黏菌素为基础联合其他类型抗生素或新型药物治疗耐碳青霉烯类肠杆菌、耐碳青霉烯类鲍曼不动杆菌、耐碳青霉烯类铜绿假单胞菌的国内外最新研究进展,以期为CR-GNB的治疗提供参考依据。Carbapenem-resistant gram-negative bacilli(CR-GNB)infection has become one of the major global public health problems.Polymyxin is mainly used in the treatment of CR-GNB infection,but the clinical efficacy of monotherapy has been questioned due to the continuous emergence of polymyxinresistant strains and related adverse reactions.Therefore,polymyxinbased drugcombination has become a research hotspot in recent years.This article reviewed the latest progress in the treatment of carbapenem-resistant enterobacter,carbapenem-resistant acinetobacter baumannii and carbapenem-resistant pseudomonas aeruginosa based on polymyxin combined with other types of antibiotics or new drugs,in order to provide reference for the treatment of CR-GNB.

关 键 词：多黏菌素 耐碳青霉烯类革兰阴性杆菌 联合用药 

分 类 号：R730[医药卫生—肿瘤]